VivoSeq
Infectious Disease

Dengue

1

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Dengue is an early-stage landscape with 1 program across 4 companies. The most active players are Hyundai Bioscience Co., Ltd., Eli Lilly, Atea Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hyundai Bioscience Co., Ltd.

1 program

PreclinicalEli Lilly logo

Eli Lilly

1 program

PreclinicalA

Atea Pharmaceuticals, Inc.

0 programs

PreclinicalNovo Nordisk logo

Novo Nordisk

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Cp-Cov03

Hyundai Bioscience Co., Ltd.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

17

clinical trials

Completed9 · 53%
Recruiting3 · 18%
Terminated2 · 12%
Not yet recruiting2 · 12%
Unknown status1 · 6%

Clinical Trials

Trial Activity

17 trials

Impact of IIT-SIT on Dengue Clusters
Recruiting·NNational Environment Agency, Singapore·N/A·NCT06894901·900 enrolled
A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy of CP-COV03 in Dengue Patients (Part 1) / Dengue and Dengue-like Illness Patients (Part 2)
Recruiting·HHyundai Bioscience Co., Ltd.·Preclinical·NCT07576868·210 enrolled
Phase 3B, Double-blind, Randomized Study to Evaluate the Safety and Non-inferiority of the Humoral Immune Response of the Butantan Dengue Vaccine in Participants Aged 60 to 79 Years Compared to Participants Aged 40 to 59 Years
Recruiting·BButantan Institute·Phase 3·NCT06891950·997 enrolled
Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169.
Not yet recruiting·MMahidol University·Phase 1·NCT05476757·5 enrolled
Adaptive Dengue Antiviral Platform Trial
Not yet recruiting·OOxford University Clinical Research Unit, Vietnam·Phase 2·NCT06551844·500 enrolled
GLS-5700 in Dengue Virus-Naïve Adults
Completed·GGeneOne Life Science, Inc.·Phase 1·NCT02809443·40 enrolled
GLS-5700 in Dengue Virus Seropositive Adults
Completed·GGeneOne Life Science, Inc.·Phase 1·NCT02887482·160 enrolled
Impact of Project Wolbachia - Singapore on Dengue Incidence
Completed·NNational Environment Agency, Singapore·N/A·NCT05505682·724,428 enrolled
A Study of INO-A002 in Healthy Dengue Virus-naive Adults
Completed·UUniversity of Pennsylvania·Phase 1·NCT03831503·30 enrolled
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
Completed·UU.S. Army Medical Research and Development Command·Phase 1·NCT02372175·27 enrolled
Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Completed·Novo Nordisk logoNovo Nordisk·Phase 2·NCT01601613·28 enrolled
TDENV PIV and LAV Dengue Prime-boost Strategy
Completed·UU.S. Army Medical Research and Development Command·Phase 1·NCT02239614·80 enrolled
Expansion of a Dengue-1 Live Virus Human Challenge
Completed·SState University of New York - Upstate Medical University·Phase 1·NCT03869060·9 enrolled
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
Completed·UUniversity of Maryland, Baltimore·Phase 1·NCT04786457·10 enrolled
Applying Wolbachia to Eliminate Dengue
Terminated·GGadjah Mada University·N/A·NCT03055585·8,173 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)